All Relations between Schizophrenia and Aripiprazole

Publication Sentence Publish Date Extraction Date Species
Ludovic Samalin, Ludivine Boudieu, Pierre Michel Llorc. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults. Expert review of neurotherapeutics. 2024-02-01. PMID:38299536. evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar i disorder in adults. 2024-02-01 2024-02-03 Not clear
Juan José Fernández-Miranda, Silvia Díaz-Fernández, Francisco Javier Cepeda-Piorno, Francisco López-Muño. Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. Biomedicines. vol 12. issue 1. 2024-01-23. PMID:38255270. an observational, prospective, one-year follow-up study was carried out with patients (n = 68) with severe schizophrenia treated with paliperidone three-month (pp3m) or aripiprazole one-month (arim). 2024-01-23 2024-01-25 human
Florian W Adraoui, Kenza Hettak, Geoffrey Viardot, Magali Alix, Sabrina Guiffard, Benoît Meot, Philippe L'Hostis, Anne Maurin, Eric Delpy, Christophe Drieu La Rochelle, Kevin Carvalh. Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model. International journal of molecular sciences. vol 25. issue 2. 2024-01-23. PMID:38256109. differential effects of aripiprazole on electroencephalography-recorded gamma-band auditory steady-state response, spontaneous gamma oscillations and behavior in a schizophrenia rat model. 2024-01-23 2024-01-25 rat
Mehdi Akbari, Shiva Jamshidi, Sonay Sheikhi, Farhad Alijani, Parsa Kafshchi, David Taylo. Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports. Psychopharmacology. 2024-01-16. PMID:38227009. aripiprazole is an efficacious treatment for both the positive and negative symptoms of schizophrenia and is also commonly used as a mood stabilizer. 2024-01-16 2024-01-18 Not clear
Sanya Sharma, Ajeet Sidana, Shivangi Mehta, Manoj Kumar Baja. Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. Indian journal of psychiatry. vol 65. issue 10. 2023-12-19. PMID:38108052. comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. 2023-12-19 2023-12-21 Not clear
Bernhard T Baun. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current medical research and opinion. 2023-11-24. PMID:37999650. aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu): review of its possible role in schizophrenia therapy. 2023-11-24 2023-11-29 Not clear
Bernhard T Baun. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current medical research and opinion. 2023-11-24. PMID:37999650. taken together, since aripiprazole may be a good treatment choice for many patients based on its favorable safety and tolerability profile, and given the advantages of lai treatment over oral treatment and the advantages of reduced dosing frequency, ari 2mrtu 960 may become an important treatment option for many clinically stable patients with schizophrenia. 2023-11-24 2023-11-29 Not clear
Christoph U Correll, Andreas Brieden, Wolfgang Janetzk. Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-11-07. PMID:37935711. symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. 2023-11-07 2023-11-20 Not clear
Christoph U Correll, Andreas Brieden, Wolfgang Janetzk. Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-11-07. PMID:37935711. we undertook a post hoc analysis of pre-stabilized outpatients with schizophrenia and complete outcome data who had been enrolled in a 6-month non-interventional study of aripiprazole once-monthly (aom) at 75 german sites. 2023-11-07 2023-11-20 Not clear
Juan J Fernández-Miranda, Silvia Díaz-Fernánde. Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety. Neuropsychiatric disease and treatment. vol 19. 2023-10-11. PMID:37818449. plasmatic levels and response to variable doses of monthly aripiprazole and three-month paliperidone in patients with severe schizophrenia. 2023-10-11 2023-10-15 Not clear
Jason Poulos, Sharon-Lise T Normand, Katya Zelevinsky, John W Newcomer, Denis Agniel, Haley K Abing, Marcela Horvitz-Lenno. Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses. Psychological medicine. 2023-09-27. PMID:37753625. individuals with schizophrenia exposed to second-generation antipsychotics (sga) have an increased risk for diabetes, with aripiprazole purportedly a safer drug. 2023-09-27 2023-10-07 Not clear
Daniel Schöttle, Klaus Wiedemann, Christoph U Correll, Wolfgang Janetzky, Michael Friede, Holger Jahn, Andreas Briede. Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly. Schizophrenia research. vol 260. 2023-09-08. PMID:37683508. response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly. 2023-09-08 2023-10-07 Not clear
Leslie Citrome, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Clodagh Beckham, Zhen Zhang, Frank Larsen, Matthew Harli. Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study. The Journal of clinical psychiatry. vol 84. issue 5. 2023-09-06. PMID:37672016. safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with schizophrenia in a randomized, open-label, parallel-arm, pivotal study. 2023-09-06 2023-10-07 Not clear
Magdalena Górny, Anna Bilska-Wilkosz, Małgorzata Iciek, Zofia Rogóż, Elżbieta Lorenc-Koc. Treatment with aripiprazole and N-acetylcysteine affects anaerobic cysteine metabolism in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. The FEBS journal. 2023-08-30. PMID:37646112. treatment with aripiprazole and n-acetylcysteine affects anaerobic cysteine metabolism in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. 2023-08-30 2023-09-07 rat
Vanessa Sanchez-Gistau, María José Moreno, Susana Gómez-Lus, Antoni Sicras-Mainar, Benedicto Crespo-Facorr. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study. Frontiers in psychiatry. vol 14. 2023-08-21. PMID:37599866. healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: ambition, a real-world study. 2023-08-21 2023-09-07 Not clear
Vanessa Sanchez-Gistau, María José Moreno, Susana Gómez-Lus, Antoni Sicras-Mainar, Benedicto Crespo-Facorr. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study. Frontiers in psychiatry. vol 14. 2023-08-21. PMID:37599866. this study aims to compare the hospitalization rate in individuals with schizophrenia who started their treatment with aripiprazole once monthly (aom400) or atypical oral antipsychotics (oa) in spain. 2023-08-21 2023-09-07 Not clear
Cailian Lu, Shan Li, Lin Kang, Qianqian Li, Hongxu Chen, Yanwen Lin, Han Zhang, Ziling Tang, Meiyan Bai, Peng Xion. Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Neuroscience letters. 2023-07-26. PMID:37495071. aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. 2023-07-26 2023-08-14 mouse
Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. 2023-07-25 2023-08-14 Not clear
Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. aripiprazole is recommended for routine use in schizophrenia patients. 2023-07-25 2023-08-14 Not clear
Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. however, the biological mechanism for the adverse drug reactions (adrs) among schizophrenia patients with the antipsychotic drug aripiprazole is far from clear. 2023-07-25 2023-08-14 Not clear